API Suppliers
0
US DMFs Filed
0
CEP/COS Certifications
0
JDMFs Filed
0
EU WC
0
Listed Suppliers
0
0
0
USA (Orange Book)
0
Europe
0
Canada
0
Australia
0
South Africa
0
Uploaded Dossiers
0
U.S. Medicaid
0
Annual Reports
0
0
USFDA Orange Book Patents
0
USFDA Exclusivities
0
Blog #PharmaFlow
0
News
0
EDQM
0
USP
0
JP
0
Other Listed Suppliers
0
0
Details:
DS-7300,s an investigational B7-H3 directed ADC is comprised of a humanized anti-B7-H3 IgG1 monoclonal antibody attached to a number of topoisomerase I inhibitor payloads (an exatecan derivative, DXd) via tetrapeptidebased cleavable linkers.
Lead Product(s): O-(3,5-Dichlorophenyl)hydroxylamine
Therapeutic Area: Oncology Product Name: DS-7300
Highest Development Status: Phase IIProduct Type: Large molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable July 20, 2022
Details:
DS-7300, a B7-H3 directed DXd antibody drug conjugate (ADC) showed promising early clinical activity in patients with several types of advanced solid tumors that are refractory or intolerable to standard treatment or for whom no standard treatment exists.
Lead Product(s): O-(3,5-Dichlorophenyl)hydroxylamine
Therapeutic Area: Oncology Product Name: DS-7300
Highest Development Status: Phase I/ Phase IIProduct Type: Large molecule
Partner/Sponsor/Collaborator: Sarah Cannon Research Institute
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable September 17, 2021